Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

NCT02239146 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Acquired Bleeding Disorder
Cardiac Surgery Requiring Cardiopulmonary Bypass

Interventions

DRUG: catridecacog
DRUG: placebo

Sponsor

Novo Nordisk A/S